If a COVID-19 vaccine were authorized for emergency use, it would occur without pre-license inspections of the manufacturing facilities, a US FDA official acknowledged at a 22 October meeting of the agency’s Vaccines and Related Biological Products Advisory Committee.
The agency might instead simply visit
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?